Maully J. Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maully J. Shah has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Beatrijs Bloemers
Department of Pediatrics, Wilhelmina Children’s Hospital
1 shared publicationF Farzana
1 shared publicationJoseph Rossano
Department of Pediatrics, University of Washington School of Medicine, Seattle, USA
1 shared publicationKottoorathu M Cherian
Division of Cardiology and Cardiothoracic Surgery, Institute of Cardiovascular Diseases, Madras Medical Mission, Madras, India
1 shared publicationN Gachara
Division of Pediatric Cardiology, Institute of Cardiovascular Disease, Madras Medical Mission, Chennai
1 shared publicationNarayanswami Sreeram
Department of Pediatrics, Wilhelmina Children’s Hospital
1 shared publication
Latest Publications
- Open Access
- 1 September 2003
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 112 (3) , e228-e233
Efficacy of Implantable Loop Recorders in Establishing Symptom-Rhythm Correlation in Young Patients With Syncope and Palpitations
Objective. To evaluate efficacy of the recently introduced implantable loop recorder (ILR) in establishing symptom-rhythm correlation in young patients with syncope, near syncope, palpitations, and acute life-threatening events (ALTEs). Methods. A retrospective study was conducted with patients with ILR from 3 pediatric centers. Inclusion criteria were age ≤25 years and a minimum follow-up of 1 month. All ILR-stored events were analyzed regularly for the presence or absence of an arrhythmia at the time of the symptomatic event. Results. Twenty-one patients (12 male, 9 female) with an average age of 12.3 ± 5.3 years (range: 0.8–22 years) were included in the study. Five (24%) patients had structural heart disease, 2 (10%) had a family history of sudden cardiac death, 3 (14%) had QT prolongation on electrocardiogram, and 11 had no cardiovascular disease. Indications for ILR were recurrent syncope and near syncope (n = 15), palpitations (n = 2), and ALTE (n = 2). Fourteen (67%) patients continued to have symptoms, and 7 (33%) had no symptoms after ILR over a follow-up period of 8.4 ± 4.7 months (range: 1.9–16 months). Symptom-rhythm correlation was possible in all 14 patients who continued to have symptoms (supraventricular tachycardia in 4, ventricular tachycardia in 2, torsades de points in 1, asystole in 1, junctional bradycardia in 1, and sinus rhythm in 5). Conclusions. ILR is useful in determining the presence or absence of an arrhythmia during symptoms of syncope, near syncope, and palpitations as well as ALTEs in patients with and without structural heart disease when conventional diagnostic testing, such as electrocardiogram, Holter monitoring, and/or external loop recording, is inconclusive.
- 1 September 2003
- Published by American Academy of Pediatrics (AAP) in Pediatrics
- Vol. 112 (3) , e228-e233
Open AccessEfficacy of Implantable Loop Recorders in Establishing Symptom-Rhythm Correlation in Young Patients With Syncope and Palpitations
Objective. To evaluate efficacy of the recently introduced implantable loop recorder (ILR) in establishing symptom-rhythm correlation in young patients with syncope, near syncope, palpitations, and acute life-threatening events (ALTEs). Methods. A retrospective study was conducted with patients with ILR from 3 pediatric centers. Inclusion criteria were age ≤25 years and a minimum follow-up of 1 month. All ILR-stored events were analyzed regularly for the presence or absence of an arrhythmia at the time of the symptomatic event. Results. Twenty-one patients (12 male, 9 female) with an average age of 12.3 ± 5.3 years (range: 0.8–22 years) were included in the study. Five (24%) patients had structural heart disease, 2 (10%) had a family history of sudden cardiac death, 3 (14%) had QT prolongation on electrocardiogram, and 11 had no cardiovascular disease. Indications for ILR were recurrent syncope and near syncope (n = 15), palpitations (n = 2), and ALTE (n = 2). Fourteen (67%) patients continued to have symptoms, and 7 (33%) had no symptoms after ILR over a follow-up period of 8.4 ± 4.7 months (range: 1.9–16 months). Symptom-rhythm correlation was possible in all 14 patients who continued to have symptoms (supraventricular tachycardia in 4, ventricular tachycardia in 2, torsades de points in 1, asystole in 1, junctional bradycardia in 1, and sinus rhythm in 5). Conclusions. ILR is useful in determining the presence or absence of an arrhythmia during symptoms of syncope, near syncope, and palpitations as well as ALTEs in patients with and without structural heart disease when conventional diagnostic testing, such as electrocardiogram, Holter monitoring, and/or external loop recording, is inconclusive.
- 30 June 2003
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 26 (7p1) , 1519-1522
Temporary Transvenous Pacing with an Active Fixation Bipolar Lead in Children:
Various techniques and electrode catheters have been developed for effective and safe temporary transvenous cardiac pacing. In neonates and children, lead dislodgment and myocardial perforation have been attendant risks with passive fixation leads. We report our experience with the recently introduced Medtronic 6416 active fixation bipolar lead in a small group of children. Between January 2000 and February 2002, 4 children (2 boys, 2 girls) underwent temporary transvenous pacing with the Medtronic 6416 lead. The median age at implantation was 4.25 years (range: 5 days–13 years), median weight was 14.5 kg (range: 2.5 kg–54 kg) and the median duration of temporary pacing was 19.5 days (range: 5–38 days). The indication for temporary pacing was AV block (n = 2), sinus arrest (n = 1) and sinus node dysfunction (n = 1). The acute pacing threshold was
- 30 June 2003
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 26 (7p1) , 1519-1522
Temporary Transvenous Pacing with an Active Fixation Bipolar Lead in Children:
Various techniques and electrode catheters have been developed for effective and safe temporary transvenous cardiac pacing. In neonates and children, lead dislodgment and myocardial perforation have been attendant risks with passive fixation leads. We report our experience with the recently introduced Medtronic 6416 active fixation bipolar lead in a small group of children. Between January 2000 and February 2002, 4 children (2 boys, 2 girls) underwent temporary transvenous pacing with the Medtronic 6416 lead. The median age at implantation was 4.25 years (range: 5 days–13 years), median weight was 14.5 kg (range: 2.5 kg–54 kg) and the median duration of temporary pacing was 19.5 days (range: 5–38 days). The indication for temporary pacing was AV block (n = 2), sinus arrest (n = 1) and sinus node dysfunction (n = 1). The acute pacing threshold was
- 18 July 2001
- Vol. 53 (1) , 74-8
Efficacy and safety of carvedilol in infants with dilated cardiomyopathy: a preliminary report.
Carvedilol has proven to be beneficial in a majority of adult patients with congestive heart failure. Although the experience from adult patients may be extrapolated to older children, symptomatic infants remain a subset for whom dosage, safety and efficacy need to be established. The purpose of this study was to assess whether treatment with carvedilol is efficacious and safe for infants with dilated cardiomyopathy who do not show satisfactory clinical improvement despite treatment with conventional medications. Eight infants with dilated cardiomyopathy (ejection fraction <30%) who were symptomatic despite tailored treatment with decongestive medications, were enrolled in the study. Echocardiographic findings and heart failure symptom scores were analyzed before and after starting carvedilol. Patients were hospitalized and monitored for side-effects during up-titration of carvedilol. At a follow-up of 4.5+/-2.2 months, patients receiving carvedilol showed a significant improvement in the left ventricular ejection fraction (38.5+/-11% v. 24.4+/-5%), and heart failure symptom score (p<0.05). No adverse events related to carvedilol administration occurred. There were no deaths. Carvedilol is well tolerated in infants with dilated cardiomyopathy and there is significant improvement in their functional status. Optimal timing of starting therapy, dosage and long-term effects need to be investigated with multi-institutional trials.
- 18 July 2001
- Vol. 53 (1) , 74-8
Efficacy and safety of carvedilol in infants with dilated cardiomyopathy: a preliminary report.
Carvedilol has proven to be beneficial in a majority of adult patients with congestive heart failure. Although the experience from adult patients may be extrapolated to older children, symptomatic infants remain a subset for whom dosage, safety and efficacy need to be established. The purpose of this study was to assess whether treatment with carvedilol is efficacious and safe for infants with dilated cardiomyopathy who do not show satisfactory clinical improvement despite treatment with conventional medications. Eight infants with dilated cardiomyopathy (ejection fraction <30%) who were symptomatic despite tailored treatment with decongestive medications, were enrolled in the study. Echocardiographic findings and heart failure symptom scores were analyzed before and after starting carvedilol. Patients were hospitalized and monitored for side-effects during up-titration of carvedilol. At a follow-up of 4.5+/-2.2 months, patients receiving carvedilol showed a significant improvement in the left ventricular ejection fraction (38.5+/-11% v. 24.4+/-5%), and heart failure symptom score (p<0.05). No adverse events related to carvedilol administration occurred. There were no deaths. Carvedilol is well tolerated in infants with dilated cardiomyopathy and there is significant improvement in their functional status. Optimal timing of starting therapy, dosage and long-term effects need to be investigated with multi-institutional trials.
- 30 September 2000
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 70 (3) , 971-973
L→R shunt: a serious consequence of TAPVC repair without ligation of vertical vein
- 30 September 2000
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 70 (3) , 971-973
L→R shunt: a serious consequence of TAPVC repair without ligation of vertical vein